Data from a man or woman who sat in front of a screen in the early 2010s, watched a triangle slowly emerge from a field of shifting dots, and pressed a button a fraction of a second slower than most of the other participants can be found somewhere in a research archive in Norfolk, England. They, the researchers recording the results, and everyone else at the time didn’t care about that delay. They returned home and carried on with their lives. They received a dementia diagnosis about ten years later. As it happened, that small hesitancy was already a warning. It had been sent for years by the brain.
Two large population studies, one tracking over 8,600 people in Norfolk, England, and the other tracking over 2,200 participants in Australia, have yielded a central and quietly unsettling finding: vision decline may be one of the earliest measurable signs that the brain is beginning to deteriorate, appearing up to twelve years before a clinical diagnosis of dementia.
| Category | Details |
|---|---|
| UK vision study | Loughborough University, 2024 — 8,623 healthy participants in Norfolk, England; followed for multiple years; 537 developed dementia; visual sensitivity test used to detect risk up to 12 years before diagnosis |
| Vision test method | Participants pressed a button upon seeing a triangle emerge from a field of moving dots on a screen; those who would later develop dementia responded significantly slower |
| Australian study | 2,281 participants; deteriorating visual acuity significantly predicted poorer problem-solving, memory, and attention scores over a 12-year period; social isolation found to partially mediate the link between vision decline and cognitive performance |
| AI / machine learning tool | University of Cambridge & The Alan Turing Institute — team led by Prof. Zoe Kourtzi; algorithm trained on MRI brain scans to detect structural grey matter loss associated with early Alzheimer’s |
| Algorithm accuracy | Over 80% accurate in predicting which patients with mild cognitive impairment would go on to develop Alzheimer’s disease; also estimates speed of cognitive decline |
| Why early detection matters | Molecular and cellular brain changes begin years before any symptoms; most clinical drug trials fail partly because treatment begins too late, after significant damage has already occurred |
| Clinical trial status | Led by Dr. Timothy Rittman, Addenbrooke’s Hospital (Cambridge University Hospitals NHS); approx. 80 patients enrolled across NHS trusts in Cambridge, Peterborough, and Brighton |
| Lancet Commission finding | 2024 Lancet Commission on dementia identified vision loss in late life as a new risk factor — contributing to up to 2.2% of dementia cases; recommended universal screening and treatment for vision loss |
| Comparison risk factor | Untreated hearing loss in mid-life contributes to an estimated 7% of dementia cases — currently a larger known contributor than vision loss |
| Vision changes linked to Alzheimer’s | Reduced contrast sensitivity; difficulty distinguishing blue-green colour spectrum; impaired inhibitory control of eye movements; increased distraction by peripheral stimuli |
| Biological mechanism | Toxic amyloid plaques may first accumulate in brain regions associated with vision before spreading to memory centres — meaning visual deficits may precede memory symptoms |
| Preventive interventions if caught early | Blood pressure management, improved diet and exercise, smoking cessation, correcting vision impairment (cataracts, glasses) — all may slow disease progression if applied pre-symptom |
According to a UK study conducted by researchers at Loughborough University, individuals who scored lower on a basic visual sensitivity test had a markedly higher chance of developing dementia within the next ten years. Not even slightly more probable. Much more likely. Furthermore, statistical noise did not obscure this subtle effect. The 2024 Lancet Commission on Dementia officially added vision loss in later life to its list of established risk factors for cognitive decline because it was consistent enough.
In retrospect, the biology underlying this is worth considering because it alters the overall appearance of the illness. Alzheimer’s disease-related toxic amyloid plaques, which are protein clumps that obstruct neural pathways and impair brain function, may start to build up in the brain’s visual processing regions before moving on to the memory-related areas. This implies that the typical perception of Alzheimer’s that most people have, in which memory loss is the initial symptom, may actually be a late manifestation of an issue that began elsewhere. In other words, vision tests may identify what memory tests fail to identify, and they may do so years earlier.
In parallel, a different and possibly more potent tool is being developed. A team led by Professor Zoe Kourtzi at the University of Cambridge, in collaboration with The Alan Turing Institute, has developed a machine learning algorithm that analyzes structural changes in MRI brain scans, particularly the progressive loss of grey matter, and uses those patterns to predict whether and how quickly an individual with early cognitive symptoms will develop Alzheimer’s. The algorithm achieves over 80% accuracy in determining who will advance when paired with findings from common memory tests. It has occasionally found patients who had not yet displayed any symptoms at all.
It’s difficult to ignore that for a little while. A patient enters a hospital in a state of well-being or nearly so. An algorithm trained on thousands of previous cases is fed a scan, and the results indicate, with significant statistical confidence, that Alzheimer’s is probably coming, maybe five to ten years away. The science has yet to provide a complete answer to the profoundly human question of what to do with that information. However, the alternative—learning about the illness only after it has caused years of harm—has significant costs of its own.
Timing is one of the factors contributing to the depressing failure rate of dementia clinical trials. The disease has often progressed to the point where interventions can, at most, slow decline by the time patients are enrolled, exhibiting noticeable symptoms, and starting treatment. Early detection—not just a few months ahead of a formal diagnosis, but years ahead—could change the entire window for treatment and provide researchers with a chance to test medications before the damage is irreparable. According to Dr. Timothy Rittman of Addenbrooke’s Hospital in Cambridge, who is overseeing the algorithm’s clinical trial across multiple NHS trusts, early diagnosis provides patients with clarity and time to prepare, and it gives medicine the window it currently lacks.
Beyond the science, the low cost and non-invasive nature of the approach is what makes vision-detection research so fascinating. a screen with a field of moving dots. pressing a button. equipment that might theoretically be found in a community health clinic or a general practitioner’s office instead of a specialized imaging facility. Even though the MRI-based algorithm is more technically complex, it does not necessitate the invasive lumbar punctures that are currently a part of many diagnostic pathways. These tools should be taken seriously at scale for practical reasons as well as scientific ones.
Whether or when either strategy will be integrated into standard medical care is still up in the air. The Cambridge trial is still in progress, and it is rarely as easy as the numbers indicate to translate research accuracy into practical clinical utility. However, researchers now view Alzheimer’s less as a disease that manifests itself through memory and more as a gradual, protracted process that has been going on for years without the affected person realizing anything is missing. That shift was not produced by the algorithm. However, it might be one of the most obvious tools available for taking action.
